Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-12-18Clinical Trial Update: Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL [Phase 1]
A Phase 1 trial assessed the safety and tolerability of combining SGN-40 (dacetuzumab) with rituximab and gemcitabine in patients with diffu…
-
CLINICAL_TRIALS trial_result · 2014-12-18Clinical Trial Update: A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma [Phase 1]
A Phase 1 safety study of SGN-40 (brentuximab vedotin) in patients with Non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2014-12-18Clinical Trial Update: A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies [Phase 1]
An early-phase Phase I dose-escalation study of Brentuximab vedotin (SGN-35) alone and in combination with gemcitabine for CD30-positive mal…
-
CLINICAL_TRIALS trial_result · 2014-12-12Clinical Trial Update: Cardiac Safety Study of Brentuximab Vedotin (SGN-35) [Phase 1]
Phase 1 cardiac safety study of brentuximab vedotin (SGN-35) has completed, providing early safety data in lymphoma patients.
-
CLINICAL_TRIALS trial_result · 2014-12-10Clinical Trial Update: Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL) [Phase 2]
A Phase 2 pilot trial evaluating intravenous vitamin C in patients with refractory non-Hodgkin lymphoma was terminated; results were posted …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-12-09Clinical Trial Update: Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation [Phase 3]
A Phase 3 trial evaluating mobilization and collection of 5×10^6 CD34+ cells/kg in non-Hodgkin's lymphoma patients using a combination of pl…
-
CLINICAL_TRIALS trial_result · 2014-12-05Clinical Trial Update: Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma [Phase 2]
A Phase 2 trial of a trivalent baculovirus-expressed influenza HA vaccine in adults with Non-Hodgkin's B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2014-12-04Clinical Trial Update: A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL) [Phase 3]
Phase 3 trial evaluating Rituximab (MabThera) in elderly patients with untreated follicular lymphoma has completed. Results from the study h…
-
CLINICAL_TRIALS trial_result · 2014-12-02Clinical Trial Update: A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment [Phase 1]
Phase I study of ChiLob 7/4, a chimeric anti-CD40 monoclonal antibody, in patients with advanced cancers refractory to conventional treatmen…
-
CLINICAL_TRIALS research · 2014-11-13Clinical Trial Update: PEARL Study: Improvement of Non-Hodgkin's Lymphoma Care [NA]
Clinical trial update for the PEARL study on improving care for Non-Hodgkin lymphoma. The trial status is currently unknown.
-
CLINICAL_TRIALS trial_result · 2014-11-10Clinical Trial Update: A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives [Phase 2]
Phase 2 clinical trial investigating a two-step bone marrow transplant using cells from two partially matched relatives was terminated; resu…
-
FDA approval · 2014-11-05FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for doxorubicin hydrochloride (Fresenius Kabi USA, LLC) under anANDA to support its generic product.
-
CLINICAL_TRIALS trial_result · 2014-11-04Clinical Trial Update: A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 study of Rituximab (MabThera/Rituxan) in patients with relapsed centroblastic-centrocytic non-Hodgkin lymphoma has completed, with r…
-
CLINICAL_TRIALS trial_result · 2014-11-03Clinical Trial Update: PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation [Phase 4]
This Phase 4 trial update reports the completion of the PROMPT study evaluating palifermin for reducing oral mucositis in peripheral blood s…
-
CLINICAL_TRIALS trial_result · 2014-10-27Clinical Trial Update: A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas [Phase 2]
A Phase II study of PXD101 (belinostat) in recurrent or refractory cutaneous T-cell lymphoma and peripheral T-cell lymphoma was terminated; …
-
FDA approval · 2014-10-25FDA Approved: CYCLOPHOSPHAMIDE — Supplemental Application (Civica, Inc.)
FDA approved a supplemental application for Civica, Inc. to market a generic cyclophosphamide product.
-
CLINICAL_TRIALS trial_result · 2014-10-24Clinical Trial Update: Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps [Phase 1, Phase 2]
This Phase 1/2 study evaluated a two-step reduced-intensity conditioning regimen for bone marrow transplantation in patients with hematologi…
-
CLINICAL_TRIALS trial_result · 2014-10-21Clinical Trial Update: Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating chemotherapy before autologous stem cell transplantation with or without rituximab in relapsed/refractory aggressiv…
-
CLINICAL_TRIALS trial_result · 2014-10-06Clinical Trial Update: Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma [Phase 2]
This Phase 2 trial evaluated the combination of fludarabine and rituximab for marginal zone non-Hodgkin's lymphoma (MALT lymphoma) and has c…
-
CLINICAL_TRIALS trial_result · 2014-10-02Clinical Trial Update: Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma [Phase 3]
Phase 3 trial comparing pegfilgrastim given on Day +3 versus Day +1 after salvage chemotherapy in patients with refractory or relapsed aggre…
-
CLINICAL_TRIALS trial_result · 2014-09-30Clinical Trial Update: Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy [Phase 2]
Phase 2 trial update shows mild-dose IMRT after GELOX chemotherapy achieving complete tumor response in early-staged extranodal nasal-type N…
-
CLINICAL_TRIALS trial_result · 2014-09-11Clinical Trial Update: Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) [Phase 1, Phase 2]
Phase 1/2 safety and tolerability study of SNS01-T in relapsed or refractory B-cell malignancies sponsored by Senesco Technologies. The tria…
-
CLINICAL_TRIALS trial_result · 2014-09-11Clinical Trial Update: Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL [Phase 1]
Phase I trial of Clofarabine with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplant for high-risk or refr…
-
CLINICAL_TRIALS trial_result · 2014-09-11Clinical Trial Update: Investigation of the Cylex® ImmuKnow® Assay
A completed clinical trial investigating the Cylex ImmuKnow immune function assay across several hematologic diseases.
-
CLINICAL_TRIALS trial_result · 2014-09-08Clinical Trial Update: T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE [NA]
A clinical trial evaluating REGKINE for T-regulatory cell kinetics in stem cell transplantation was terminated, and results have been posted…